Foreign Drug Makers Consider Japanese Market More Important Than Japanese Drug Companies
This article was originally published in PharmAsia News
Executive Summary
According to a recent survey conducted by Booz & Company on the pharmaceutical industry for the next 10 years in Japan, 38 percent of foreign pharmaceutical companies operating in Japan consider the Japanese market very important to them. In contrast, 27 percent of Japanese major pharmaceutical companies and 18 percent of middle sized drug makers share the same view. Among the major Japanese drug makers, 36 percent plans to focus on overseas market. Out of 248 target foreign and Japanese domestic companies, 35 companies answered the survey. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.